TICAGRELOR (ticagrelor) by Gen Pharmaceuticals is p2y12 receptor antagonists [moa]. Approved for cardiovascular (cv) death, myocardial infarction (mi), stroke in patients with acute coronary syndrome (acs) and 7 more indications. First approved in 2025.
Drug data last refreshed 21h ago
P2Y12 Receptor Antagonists
P2Y12 Platelet Inhibitor
Worked on TICAGRELOR at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants
Ticagrelor Tablets 90 mg Relative to Originator Ticagrelor Tablets 90 mg
Ticagrelor De-escalation Strategy in AMI Patients
Disparities in the Proportion of Ticagrelor and Prasugrel-eligible Patients with Acute Coronary Syndrome in a Real-world Registry
A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants